Researchers at Boston Children’s Hospital used stem cell technology to create cerebellar cells known as Purkinje cells from patients with tuberous sclerosis complex (TSC), a genetic syndrome that often includes autism spectrum disorder-like features. In the lab, the cells showed several characteristics that may help explain how autism spectrum disorder (ASD) develops at the molecular level.
Increasing evidence has linked autism spectrum disorder (ASD) with dysfunction of the brain’s cerebellum, but the details have been unclear.
TSC, a rare condition in which benign tumors grow in multiple organs of the body, is associated with ASD in about half of all cases. Previous brain autopsies have shown that patients with TSC, as well as patients with ASD, have reduced numbers of Purkinje cells, the main type of neuron that communicates out of the cerebellum.
In a 2012 mouse study, Sahin and colleagues knocked out a TSC gene (Tsc1) in Purkinje cells and found social deficits and repetitive behaviors in the mice, together with abnormalities in the cells.
Stem Cell Derived Neurons
Sahin and colleagues took their observations to humans in their latest study, studying Purkinje cells derived from three patients with TSC (two also had ASD symptoms, and all three also had epilepsy).
“Developmentally, stem-cell derived neurons are close to a fetal state, recapitulating early differentiation of cells,"
said Maria Sundberg, PhD, the paper’s first author.
To make the cells, Sundberg first created induced pluripotent stem cells from patients’ blood cells or skin cells, then differentiated these into neural progenitor cells and finally Purkinje cells. The team then compared them with Purkinje cells derived from unaffected people (parents or gender-matched controls) and with cells whose TSC mutation was corrected using CRISPR-Cas9 gene editing.
“We saw changes,” said Sahin. “The cells are bigger and fire less than control cells - exactly what we see in the mouse model."
Purkinje cells with the TSC genetic defect were harder to differentiate from neural progenitor cells, suggesting that TSC may impair the early development of cerebellar tissue. On examination, the patient-derived Purkinje cells showed structural abnormalities in dendrites and signs of impaired development of synapses.
The TSC Purkinje cells also showed over-activation of a cell growth pathway called mTOR. Accordingly, the team treated the cells with rapamycin, an mTOR inhibitor that is already used clinically in TSC to reduce the size of TSC-related tumors and prevent TSC-related seizures.
Added to patient-derived cells in culture, rapamycin enabled the development of more Purkinje precursor cells, improved the functioning of their synapses and increased their tendency to fire.
Finally, the researchers also compared what genes were being “turned on” in Purkinje cells from TSC patients versus controls. Unexpectedly, the patient-derived cells showed reduced production of FMRP, a protein that is associated with Fragile X syndrome, a common genetic cause of ASD and intellectual disability. FMRP is known to help regulate synapse function, so it may contribute to the abnormalities seen in Purkinje cell functioning in TSC.
“These conditions may have a common downstream pathway,"
The analysis also showed reduced production of two proteins important for neuron-to-neuron communication at synapses: synaptophysin and a glutamate receptor protein.
The study was the first to create human Purkinje cells using TSC patients’ own stem cells. In future studies, Sahin and colleagues hope to generate larger numbers of patient-derived cells to investigate differences between patients with TSC alone and those who also have ASD.
Additionally, they hope to use the Purkinje cell platform to study other ASD-related genetic disorders, including Fragile X and SHANK3 mutation, and to test potential drugs. Sundberg also plans to create other types of neurons for modeling ASD.
“Looking at cell-type-specific changes is very important. In TSC, we know that in different cell types, the mutation causes different effects,"
The study was funded by U.S. Army Medical Research Tuberous Sclerosis Complex Research Program, Nancy Lurie Marks Family Foundation, Harvard Stem Cell Institute, and the Children’s Hospital Boston Translational Research Program (to MS). The project was co-sponsored by the Iris and Jumming Le Foundation and the Rockefeller University Center for Clinical and Translational Science.
Maria Sundberg, Ivan Tochitsky, David E. Buchholz, Kellen Winden, Ville Kujala, Kush Kapur, Deniz Cataltepe, Daria Turner, Min-Joon Han, Clifford J. Woolf, Mary E. Hatten & Mustafa Sahin Purkinje cells derived from TSC patients display hypoexcitability and synaptic deficits associated with reduced FMRP levels and reversed by rapamycin Molecular Psychiatry (2018) doi:10.1038/s41380-018-0018-4
Image: Purkinje neuron derived from patients with tuberous sclerosis and model properties of the disease at the cellular and molecular level. Credit: Courtesy Maria Sundberg, PhD, Sahin Laboratory, Boston Children’s Hospital